How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,387 results for

adhd Cognitive behavioural therapy

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial. Full Text available with Trip Pro

Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial. Adult attention-deficit/hyperactivity disorder (ADHD) is prevalent but often unrecognized, in part because it tends to co-occur with other disorders such as substance use disorders. Cocaine use disorder is one such disorder with high co-occurrence of ADHD.To examine whether treatment of co-occurring ADHD and cocaine use disorder (...) with cognitive behavioral therapy are effective for treatment of co-occurring ADHD and cocaine use disorder, both improving ADHD symptoms and reducing cocaine use. The data suggest the importance of screening and treatment of ADHD in adults presenting with cocaine use disorder.clinicaltrials.gov Identifier:NCT00553319.

2015 JAMA psychiatry (Chicago, Ill.) Controlled trial quality: predicted high

82. The angiotensin converting enzyme inhibitor, captopril, prevents the hyperactivity and impulsivity of neurokinin-1 receptor gene ‘knockout’ mice: Sex differences and implications for the treatment of attention deficit hyperactivity disorder Full Text available with Trip Pro

The angiotensin converting enzyme inhibitor, captopril, prevents the hyperactivity and impulsivity of neurokinin-1 receptor gene ‘knockout’ mice: Sex differences and implications for the treatment of attention deficit hyperactivity disorder Mice lacking functional neurokinin-1 receptors (NK1R-/-) display behavioural abnormalities resembling attention deficit hyperactivity disorder (ADHD): locomotor hyperactivity, impulsivity and inattentiveness. The preferred ligand for NK1R, substance P (...) , is metabolised by angiotensin converting enzyme (ACE), which forms part of the brain renin angiotensin system (BRAS). In view of evidence that the BRAS modulates locomotor activity and cognitive performance, we tested the effects of drugs that target the BRAS on these behaviours in NK1R-/- and wildtype mice. We first tested the effects of the ACE inhibitor, captopril, on locomotor activity. Because there are well-established sex differences in both ADHD and ACE activity, we compared the effects of captopril

2015 European Neuropsychopharmacology

83. Neurofeedback and cognitive attention training for children with attention-deficit hyperactivity disorder in schools. Full Text available with Trip Pro

Neurofeedback and cognitive attention training for children with attention-deficit hyperactivity disorder in schools. To evaluate the efficacy of 2 computer attention training systems administered in school for children with attention-deficit hyperactivity disorder (ADHD).Children in second and fourth grade with a diagnosis of ADHD (n = 104) were randomly assigned to neurofeedback (NF) (n = 34), cognitive training (CT) (n = 34), or control (n = 36) conditions. A 2-point growth model assessed (...) with those in the control condition on the Conners 3-P Attention, Executive Functioning and Global Index, on all BRIEF summary indices, and on BOSS motor/verbal off-task behavior. Children who received CT showed no improvement compared to the control condition. Children in the NF condition showed significant improvements compared to those in the CT condition on Conners 3-P Executive Functioning, all BRIEF summary indices, SKAMP Attention, and Conners 3-T Inattention subscales. Stimulant medication dosage

2014 Journal of developmental and behavioral pediatrics : JDBP Controlled trial quality: uncertain

84. Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder

Participant Data (IPD) Sharing Statement: Plan to Share IPD: Undecided Keywords provided by Hospital de Clinicas de Porto Alegre: ADHD Adults treatment Methylphenidate Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Methylphenidate (...) ). Nevertheless, there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. The aim of this study is to address the clinical and genetic predictors of MPH treatment outcomes in ADHD. Condition or disease Intervention/treatment Phase Attention Deficit Disorder With Hyperactivity Drug: Immediate-release Methylphenidate Phase 4 Detailed Description: Methylphenidate (MPH) is the most prescribed psychostimulant for children and adults with Attention

2016 Clinical Trials

85. The Effects of Working Memory Training in Children With Attention-Deficit/Hyperactivity Disorder

: Chang Gung Memorial Hospital Information provided by (Responsible Party): I-hsuan Shen, Chang Gung Memorial Hospital Study Details Study Description Go to Brief Summary: Previous studies indicated that children with attention-deficit/hyperactivity disorder (ADHD) often suffer from deficits in executive function, such as attentional control, inhibition, and working memory. One of these executive functions, working memory, plays a critical role in academic performance and classroom behavior. Working (...) Party: I-hsuan Shen, Associated professor, Chang Gung Memorial Hospital ClinicalTrials.gov Identifier: Other Study ID Numbers: 104-5308A3 First Posted: November 9, 2016 Last Update Posted: October 26, 2017 Last Verified: October 2017 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior

2016 Clinical Trials

86. Depression in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD): The Mediating Role of Cognitive-Behavioral Factors Full Text available with Trip Pro

Depression in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD): The Mediating Role of Cognitive-Behavioral Factors Adults with Attention-Deficit/Hyperactivity Disorder (ADHD) are at increased risk for depressive disorders but little is known about the potential cognitive and behavioral mechanisms of risk that could shape treatment. This study evaluated the degree to which cognitive-behavioral constructs associated with depression and its treatment-dysfunctional attitudes (...) fully accounted for the variance between ADHD symptoms and depressive symptoms. Each independent variable partially mediated the other in accounting for depression symptoms suggesting overlapping and unique variance. Cognitive-behavioral avoidance, however, was more strongly related to meeting diagnostic criteria for a depressive disorder than were dysfunctional attitudes. Processes that are targeted in cognitive behavior therapy (CBT) for depression were associated with symptoms in adults with ADHD

2013 Cognitive Therapy and Research

87. Psychoeducation for adults with attention deficit hyperactivity disorder vs. cognitive behavioral group therapy: a randomized controlled pilot study. (Abstract)

Psychoeducation for adults with attention deficit hyperactivity disorder vs. cognitive behavioral group therapy: a randomized controlled pilot study. The aim of the present study was to assess the efficacy of psychoeducation as compared with cognitive behavioral group therapy in adults with attention deficit hyperactivity disorder (ADHD) who still had significant symptoms and were in pharmacological treatment. This is the first study on psychoeducation in adults with ADHD. Thirty-two (...) individuals were randomized to two treatment conditions: 15 were in the psychoeducation group and 11 were in the cognitive behavioral group therapy. A total of 30 completed treatment, and 26 completed the follow-up assessments. The results indicated that both treatments were associated with statistically significant improvements on inattention, hyperactivity, impulsivity, and self-esteem. The patients in both groups showed a decrease in anxiety symptoms and obtained significantly lower scores

2013 The Journal of nervous and mental disease Controlled trial quality: uncertain

88. Treatment for Insomnia and Disrupted Sleep Behavior in Children and Adolescents with Autism Spectrum Disorder

1 2 ABC: Aberrant Behavior Checklist 3 ASD: autism spectrum disorder 4 ADHD: attention-deficit/hyperactivity disorder 5 AEs: adverse events 6 BR: bedtime resistance 7 CAM: complementary and alternative medicine 8 CBT: cognitive behavioral therapy 9 CSHQ: Children’s Sleep Habit Questionnaire 10 CSHQ-BR: Children’s Sleep Habit Questionnaire-Bed Resistance 11 CSHQ-SOD: Children’s Sleep Habit Questionnaire-Sleep Onset Delay 12 DBC: Developmental Behavior Checklist 13 FDA: Food and Drug (...) disorder, 22 and ADHD. Children and adolescents with ASD are also more likely to use medications that 23 33 disrupt normal sleep patterns, such as stimulants, some antiseizure medicines, and psychotropic 1 medications. 2 3 Recommendation 2 rationale: Behavioral strategies 4 Environment and family factors, including child-rearing practices and bedtime routines that are 5 not conducive to good sleep, contribute to sleep disturbance in children with ASD. 49 Although 6 robust evidence for parental

2020 American Academy of Neurology

89. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder. (Abstract)

Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder. The aim of this study was to evaluate and compare the effects of atomoxetine (ATX) and osmotic release oral system-methylphenidate (OROS-MPH) therapies on executive functions, activities, treatment response time, and adverse effects based on discernible clinical effects in children with combined type attention-deficit (...) /hyperactivity disorder (ADHD).The study sample consisted of 43 children 7-12 years of age, who presented to the outpatient clinic with inattention, hyperactivity, and impulsivity for the first time, and were diagnosed as having combined type ADHD according to Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV) criteria but had not previously used any medication for ADHD. The Wisconsin Card Sorting Test (WCST), Stroop Test TBAG Form (STP), and Visual Auditory Digit Span B (VADS B) were

2015 Journal of Child and Adolescent Psychopharmacology Controlled trial quality: uncertain

90. Mindfulness Meditation Training for Attention-Deficit/Hyperactivity Disorder in Adulthood: Current Empirical Support, Treatment Overview, and Future Directions Full Text available with Trip Pro

Mindfulness Meditation Training for Attention-Deficit/Hyperactivity Disorder in Adulthood: Current Empirical Support, Treatment Overview, and Future Directions Research examining nonpharmacological interventions for adults diagnosed with attention-deficit/hyperactivity disorder (ADHD) has expanded in recent years and provides patients with more treatment options. Mindfulness-based training is an example of an intervention that is gaining promising preliminary empirical support (...) . Directions for future research, including mindfulness meditation as a standalone treatment and as a complementary approach to cognitive-behavioral therapy, are provided.

2015 Cognitive And Behavioral Practice

91. Brief Strategic Family Therapy (BSFT) for Young People in Treatment for Non?Opioid Drug Use: A Systematic Review Full Text available with Trip Pro

be equally effective. Family therapy encompasses a range of different interventions with varying theoretical sources, including behavioral and cognitive behavioral theory, structural and strategic family theory, and family systems theory ( ; ). Some reviews have suggested that these family‐based therapies are superior to individual‐based programs in reducing youth drug use ( : Lipsey, Tanner‐Smith & ; ). Young people with persistent drug use have unique needs due to their particular cognitive (...) different kinds of treatment approaches for young drug users as effective ( ; ; Williams, Chang & Addiction Centre Adolescent Research Group, 2000; ). The current dilemma in the field of substance abuse treatment for young people is that it is not clear what works best, with research suggesting that almost all interventions lead to reduced drug use. While there are some promising individually‐based cognitive and motivational therapies ( ; ; ; Galanter & Kleber, 2008), family‐based approaches may

2013 Campbell Collaboration

92. Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults [Cochrane Protocol]

Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence (...) by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about

2015 PROSPERO

93. Attention deficit/hyperactivity disorders with co-existing substance use disorder is characterized by early antisocial behaviour and poor cognitive skills. Full Text available with Trip Pro

Attention deficit/hyperactivity disorders with co-existing substance use disorder is characterized by early antisocial behaviour and poor cognitive skills. Attention Deficit/Hyperactivity Disorder (ADHD) is associated with an increased risk of co-existing substance abuse. The Swedish legislation on compulsory healthcare can be applied to persons with severe substance abuse who can be treated involuntarily during a period of six months. This context enables a reliable clinical assessment of ADHD (...) in individuals with severe substance use disorder (SUD).In the context of compulsory care for individuals with severe SUD, male patients were assessed for ADHD, co-morbid psychiatric symptoms, psychosocial background, treatment history, and cognition. The data from the ADHD/SUD group (n = 60) was compared with data from (1) a group of individuals with severe substance abuse without known ADHD (SUD group, n = 120), as well as (2) a group with ADHD from an outpatient psychiatric clinic (ADHD/Psych group, n

2013 BMC Psychiatry

94. Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial. Full Text available with Trip Pro

Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial. To test the efficacy and safety of osmotic release oral system (OROS) methylphenidate (MPH) in doses up to 180 mg/day to treat attention deficit hyperactivity disorder (ADHD) and prevent any drug relapse in individuals with a co-diagnosis of ADHD and amphetamine dependence.Randomized placebo-controlled 24-week double-blind (...) ) measured by urine toxicology, retention to treatment, craving and time to relapse.The MPH-treated group reduced their ADHD symptoms during the trial (P = 0.011) and had a significantly higher proportion of drug-negative urines compared with the placebo group (P = 0.047), including more amphetamine-negative urines (P = 0.019) and better retention to treatment (P=0.032).Methylphenidate treatment reduces attention deficit hyperactivity disorder symptoms and the risk for relapse to substance use

2014 Addiction (Abingdon, England) Controlled trial quality: predicted high

95. A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants

Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: An Open, Self-Controlled, Prospective Study of Concerta on Cognitive Functions, Efficacy and Tolerance in the Pediatric Patients With Attention Deficit Hyperactivity Disorder (ADHD) Study Start Date : December 2009 Actual Primary Completion Date : November 2010 Actual Study Completion Date : November 2010 Resource links provided by the National Library of Medicine related topics: available for: Arms (...) : September 2014 Keywords provided by Xian-Janssen Pharmaceutical Ltd.: Attention Deficit Hyperactivity Disorder Methylphenidate Hydrochloride CONCERTA Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Methylphenidate Central Nervous

2013 Clinical Trials

96. Supplementation of Polyunsaturated Fatty Acids in Children With Attention Deficit/Hyperactivity Disorder (ADHD)

Department More Information Go to Layout table for additonal information Responsible Party: Magdalena Grygo, MD, Medical University of Warsaw ClinicalTrials.gov Identifier: Other Study ID Numbers: KB/154/2006 First Posted: April 15, 2014 Last Update Posted: April 15, 2014 Last Verified: April 2014 Keywords provided by Magdalena Grygo, Medical University of Warsaw: ADHD, attention deficit/hyperactivity disorder, attention deficit disorder, inattention, cognitive skills, children, polyunsaturated fatty (...) Update Posted : April 15, 2014 Sponsor: Medical University of Warsaw Information provided by (Responsible Party): Magdalena Grygo, Medical University of Warsaw Study Details Study Description Go to Brief Summary: The purpose of the study is assessing the efficacy of Omega - 3 and Omega - 6 treatment in boys with Attention-Deficit/Hyperactivity Disorder (ADHD) compared with control group healthy boys. Condition or disease Intervention/treatment Phase ADHD Dietary Supplement: Eye Q Phase 1 Phase 2

2014 Clinical Trials

97. Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder. Full Text available with Trip Pro

Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder. This study examined the effects of atomoxetine (ATX) and OROS methylphenidate (MPH) on laboratory measures of inhibitory control and attention in youth with attention-deficit/hyperactivity disorder (ADHD). It was hypothesized that performance would be improved by both treatments, but response profiles would differ because the medications work via different (...) indicated that MPH improved RT, RTSD, and omission errors more than ATX (p < .05). Changes in performance with treatment did not correlate with changes in ADHD symptoms.MPH has greater effects than ATX on CPT measures of sustained attention in youth with ADHD. However, the dissociation of cognitive and behavioral change with treatment indicates that CPT measures cannot be considered proxies for symptomatic improvement. Further research on the dissociation of cognitive and behavioral endpoints for ADHD

2014 Journal of Child Psychology and Psychiatry Controlled trial quality: uncertain

98. Cognitive-behavioural group therapy for adolescents with ADHD: study protocol for a randomised controlled trial. Full Text available with Trip Pro

Cognitive-behavioural group therapy for adolescents with ADHD: study protocol for a randomised controlled trial. Persistence of attention deficit hyperactivity disorder (ADHD) into adolescence is a significant burden to patients. Clinical guidelines recommend non-pharmacological therapies, but the evidence to support this recommendation is sparse. This study aims to evaluate the effect of a 12-week group cognitive-behavioural therapy (CBT) programme for adolescents with ADHD aged 14-18 years (...) , who still have impairing symptoms after treatment with medication. We will study the effect of the treatment on ADHD symptoms and examine moderators and mediators of the effect of the treatment on ADHD.We conduct a randomised controlled trial of CBT group therapy in adolescents with ADHD recruited from child psychiatric outpatient units in Mid-Norway. 99 adolescents who met inclusion criteria and consented to participation have been randomised to a 12-week group intervention or to a control group

2020 BMJ open

99. Cognitive Training in Children With Attention Deficit/ Hyperactivity Disorder (ADHD)

provided by Aida Bikic, Region Syddanmark: ADHD Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders (...) Cognitive Training in Children With Attention Deficit/ Hyperactivity Disorder (ADHD) Cognitive Training in Children With Attention Deficit/ Hyperactivity Disorder (ADHD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2012 Clinical Trials

100. Influence of Stimulant Medication on Brain Processes for Decision Making in Attention Deficit Hyperactivity Disorder

: Influence of Stimulant Medication on Brain Processes for Decision Making in Attention Deficit Hyperactivity Disorder Study Start Date : June 2013 Actual Primary Completion Date : June 2015 Actual Study Completion Date : June 2015 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Behavioral Cognitive testing of participants. Asterisk applies for patient group. Day 1: Patient arrives having (...) is to measure the effect of adult ADHD and methylphenidate on cerebral perfusion. This will be done through applying a novel arterial spin labelling MRI-technique on the participants in the fMRI arm of the study. Condition or disease Intervention/treatment Phase Attention Deficit-Hyperactivity Disorder Drug: Ritalin Drug: Placebo Phase 4 Detailed Description: The immediate scientific goal of this trial is to investigate the cognitive- and brain-mechanisms underlying Decision Making (DM) and instrumental

2013 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>